- Neuroleptic malignant syndrome - UpToDate
Neuroleptic malignant syndrome (NMS) is a neurologic emergency associated with the use of antipsychotic (neuroleptic) agents and characterized by a distinctive clinical syndrome of mental status change, rigidity, fever, and dysautonomia [1] Incidence rates for NMS range from 0 02 to 3 percent among patients taking antipsychotic agents [2,3]
- Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome . . .
One hundred seventy-two NMS cases and 1441 sex-, age-, and diagnosis-matched controls were included (age = 58 8 ± 13 1 years, males = 59 9%) Incidence of NMS was 1 99 (1 98–2 00) per 10 000 person-years
- Neuroleptic malignant syndrome - Orphanet
Neuroleptic malignant syndrome (NMS) occurs in 1 5,000 to 10,000 patients treated with antipsychotics or other central dopamine (D2) receptor antagonists (all age groups; male:female ratio 2:1 in some studies; higher incidence rates have been reported in the past)
- Neuroleptic malignant syndrome - Wikipedia
Neuroleptic malignant syndrome (NMS) is a rare [5][6] but life-threatening reaction that can occur in response to antipsychotics (neuroleptic) or other drugs that block the effects of dopamine [1][7] Symptoms include high fever, confusion, rigid muscles, variable blood pressure, sweating, and fast heart rate [1]
- Neuroleptic Malignant Syndrome: Symptoms Treatment
Neuroleptic malignant syndrome (NMS) can affect anyone taking neuroleptic (antipsychotic) medications Although two-thirds of NMS cases are thought to occur within the first week of starting neuroleptic medications, the syndrome may happen at any time during treatment
- Neuroleptic Malignant Syndrome (NMS)
NMS is most common after starting or increasing the dose of these types of medicines, and in 90% of cases this occurs within 10 days The onset is usually gradual over 1 to 3 days, however, it can occur at any time in those taking antipsychotic medication
- Neuroleptic Malignant Syndrome: A Systematic Review
Neuroleptic malignant syndrome (NMS) is a life-threatening condition occurring rarely when patients are exposed to neuroleptic drugs in clinical practice It can occur in both genders with similar frequency
- Neuroleptic Malignant Syndrome - psychiatryonline. org
For example, data from the U S Agency for Healthcare Research and Quality indicate that about 2,000 cases of NMS are diagnosed annually in hospitals in the United States, incurring health care costs of $70 million, with a mortality rate of 10%, which under-scores the continuing public health impact of NMS (http: hcup ahrq gov HCUPnet asp)
|